Liver/Biliary Disorders News

BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.

BOSTON — Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting.

Increased consumption of ultra-processed foods was associated with higher odds of developing metabolic dysfunction-associated steatotic liver disease in both adolescents and adults, according to research presented at The Liver Meeting.

BOSTON — Low-dose aspirin significantly reduced steatosis in patients with metabolic dysfunction-associated steatotic liver disease and improved markers of liver inflammation and fibrosis, according to data presented at The Liver Meeting.

BOSTON — Oral naltrexone 50 mg safely improved alcohol use-related parameters and decompensation, and also reduced cravings, over 1 year among patients with alcohol use disorder and compensated cirrhosis, according to a presenter.

The FDA has granted fast track designation to Chemomab Therapeutics’ anti-CCL24 monoclonal antibody, CM-101, for the treatment of adults with primary sclerosing cholangitis, according to a manufacturer release.

BOSTON — In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.

BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.

BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.

BOSTON — Response to treatment for acute kidney injury correlated with improved 90-day survival and shorter lengths of hospital stay among patients with cirrhosis waitlisted for liver transplant, according to data at The Liver Meeting.